Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Wedbush

Wedbush started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a report released on Friday, Marketbeat reports. The firm issued an outperform rating and a $18.00 target price on the stock.

A number of other brokerages have also issued reports on AVTX. BTIG Research began coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. HC Wainwright assumed coverage on Avalo Therapeutics in a research note on Thursday, October 24th. They issued a “neutral” rating for the company.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $8.44 on Friday. The company has a 50-day moving average price of $7.82 and a two-hundred day moving average price of $9.40. Avalo Therapeutics has a 52 week low of $4.20 and a 52 week high of $34.46.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC increased its position in shares of Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after purchasing an additional 915,629 shares during the period. RA Capital Management L.P. acquired a new position in Avalo Therapeutics during the third quarter worth about $9,186,000. Geode Capital Management LLC grew its holdings in Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares during the period. Bank of Montreal Can bought a new stake in Avalo Therapeutics in the fourth quarter worth about $446,000. Finally, Walleye Capital LLC acquired a new stake in Avalo Therapeutics in the 4th quarter valued at about $145,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.